Eli Lilly CFO Discusses Weight Loss Pill Launch, Business Outlook, and Pricing Strategy

Business and Growth Outlook

• 📈 Eli Lilly anticipates industry-leading growth with a midpoint of 25% for 2026, continuing the momentum from 2025.
• 🚀 The company achieved 43% revenue growth in the fourth quarter, driven by strong performance in key growth products.
• 🎯 Growth is fueled by a broad portfolio across therapeutic areas, not solely by the anti-obesity segment.

Anti-Obesity and Diabetes Market

• 💡 The anti-obesity market grew by 85% in the fourth quarter, with Eli Lilly outpacing this growth.
• diabetes market also saw strong growth of 17%.
• 🌍 Eli Lilly is expanding access to anti-obesity medications, with an agreement to provide access to over 40 million Medicare patients starting by July.

Weight Loss Pill Launch and FDA Approval

• 💊 Eli Lilly's new weight loss pill, orforglipron, submitted for regulatory approval in Q4 and expects action as early as Q2.
• 🤝 The company is actively engaging with the FDA and feels positive about the progress towards the expected Q2 regulatory action.
• 🏥 Both tirzepatide (Zepbound) and orforglipron will be available to Medicare patients, with a copay of $50.

Pricing Dynamics and Volume Growth

• 📉 The company's 2026 guide incorporates an expected price erosion of low to mid-teens.
• 💰 This price erosion is offset by strong volume growth, which is expected to more than compensate and drive the overall 25% growth target.
• 📊 Publicly available prices for government segments ($245) and direct-to-patient adjustments ($-50) are factored into the strategy.

Market Expansion and New Products

• 🎯 The obesity and type 2 diabetes markets represent a significant opportunity, with over 100 million potential patients in the US and 900 million globally.
• 🚀 The Zepbound Quick Pen received approval and is planned for market release within 30 days, offering another option for patients.
• 🌍 The Quick Pen will be available through various channels, including direct to patients, aiming for broad access.